AbbVie (ABBV) Stock Price, News & Analysis

Company Overview

AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company that researches, develops and markets advanced therapies across multiple therapeutic areas. Established in 2013 as a spin-off from Abbott Laboratories, AbbVie has built a diverse portfolio focused on immunology, oncology, neuroscience, eye care and women’s health. The company’s mission is to deliver innovative medicines that address serious health challenges and improve patient outcomes worldwide.

In immunology, AbbVie is best known for Humira (adalimumab), which has been prescribed for a range of autoimmune disorders including rheumatoid arthritis, psoriasis and Crohn’s disease. The company has continued to broaden its immunology franchise with newer assets such as Skyrizi (risankizumab) and Rinvoq (upadacitinib), targeting diseases like plaque psoriasis and rheumatoid arthritis. In oncology, AbbVie’s leading products include Imbruvica (ibrutinib) and Venclexta (venetoclax), which are used to treat various blood cancers, while its neuroscience and eye care programs advance therapies for conditions such as Parkinson’s disease and retinal disorders.

AbbVie maintains a robust pipeline supported by significant investment in research and development. The company operates research facilities in North America, Europe and Asia, collaborating with academic institutions, biotechnology firms and non-profit organizations. This collaborative approach has enabled AbbVie to pursue novel drug candidates in areas of high unmet medical need, with several late-stage programs seeking regulatory approval in the coming years.

Headquartered in North Chicago, Illinois, AbbVie has a commercial presence in more than 175 countries and employs tens of thousands of people worldwide. Under the leadership of Chairman and CEO Richard A. Gonzalez and President and COO Michael Severino, the company continues to optimize its global manufacturing and supply chain capabilities. AbbVie’s commitment to patient-centric innovation, strategic partnerships and operational excellence positions it to sustain growth and deliver long-term value to stakeholders.

AI Generated. May Contain Errors.

Key Stats

• Today's Range: $181.73 to $188.00
• 50-Day Range: $170.01 to $198.62
• 52-Week Range: $163.52 to $218.66
• Volume: 29.26 million shs
• Average Volume: 6.22 million shs
• Market Capitalization: $321.29 billion
• P/E Ratio: 77.40
• Dividend Yield: 3.61%
• Price Target: $211.29
• Consensus Rating: Moderate Buy

AbbVie Stock Analysis - MarketRank™

AbbVie scored higher than 99% of companies evaluated by MarketBeat, and ranked 11th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 16 buy ratings, 8 hold ratings, and no sell ratings.

Amount of Analyst Coverage

AbbVie has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 13.57%

Earnings Growth

Earnings for AbbVie are expected to grow by 13.57% in the coming year, from $12.31 to $13.98 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AbbVie is 77.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.01.

Price to Earnings Ratio vs. Sector

The P/E ratio of AbbVie is 77.40, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.24.

Price to Earnings Growth Ratio

AbbVie has a PEG Ratio of 1.21. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

AbbVie has a P/B Ratio of 95.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.84% of the float of AbbVie has been sold short.

Short Interest Ratio / Days to Cover

AbbVie has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AbbVie has recently decreased by 7.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

AbbVie is a leading dividend payer. It pays a dividend yield of 3.60%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

AbbVie has been increasing its dividend for 53 years.

Dividend Coverage

The dividend payout ratio of AbbVie is 279.15%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, AbbVie will have a dividend payout ratio of 46.92% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.34

Percentage of Shares Shorted

0.84% of the float of AbbVie has been sold short.

Short Interest Ratio / Days to Cover

AbbVie has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AbbVie has recently decreased by 7.49%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.38

News Sentiment

AbbVie has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 82 news articles for AbbVie this week, compared to 59 articles on an average week.

Search Interest

Only 85 people have searched for ABBV on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.

MarketBeat Follows

Only 26 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,359,427.00 in company stock.

Percentage Held by Insiders

Only 0.08% of the stock of AbbVie is held by insiders.

Percentage Held by Institutions

70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABBV Stock Analysis - Frequently Asked Questions

How have ABBV shares performed this year?

AbbVie's stock was trading at $177.70 at the start of the year. Since then, ABBV stock has increased by 2.4% and is now trading at $181.8870.
View the best growth stocks for 2025 here.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings results on Friday, April, 25th. The company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.40 by $0.06. The business's revenue was up 8.4% compared to the same quarter last year.
Read the conference call transcript.

Does AbbVie have any subsidiaries?

AbbVie subsidiaries include Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and more.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC).

Company Calendar

• Record date for 5/15 Dividend: 4/15/2025
• Ex-Dividend for 5/15 Dividend: 4/15/2025
• Last Earnings: 4/25/2025
• Dividend Payable: 5/15/2025
• Today: 6/30/2025
• Record date for 8/15 Dividend: 7/15/2025
• Ex-Dividend for 8/15 Dividend: 7/15/2025
• Next Earnings (Estimated): 7/24/2025
• Dividend Payable: 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:ABBV
• CIK: 1551152
• Web: www.abbvie.com
• Phone: (847) 932-7900
• Fax: 302-655-5049
• Employees: 55,000
• Year Founded: 2013

Price Target and Rating

• Average Stock Price Target: $211.29
• High Stock Price Target: $250.00
• Low Stock Price Target: $180.00
• Potential Upside/Downside: +16.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.81
• Research Coverage: 27 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.35
• Trailing P/E Ratio: 77.40
• Forward P/E Ratio: 14.78
• P/E Growth: 1.21
• Net Income: $4.28 billion
• Net Margins: 7.31%
• Pretax Margin: 6.31%
• Return on Equity: 412.03%
• Return on Assets: 13.11%

Debt

• Debt-to-Equity Ratio: 44.14
• Current Ratio: 0.76
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: $56.33 billion
• Price / Sales: 5.70
• Cash Flow: $14.90 per share
• Price / Cash Flow: 12.21
• Book Value: $1.90 per share
• Price / Book: 95.73

Miscellaneous

• Outstanding Shares: 1,766,400,000
• Free Float: 1,764,990,000
• Market Cap: $321.29 billion
• Optionable: Optionable
• Beta: 0.50